Legislative & Regulatory Positions

AMCP supports increased access to Prescription Digital Therapeutics (PDTs). PDTs are software-based therapies that deliver clinical benefits to patients, either alone or in combination with other forms of treatment. These therapeutics require a prescription and are subject to oversight by the Food and Drug Administration (FDA). To be approved by the FDA, PDTs must demonstrate both safety and efficacy.

AMCP opposes legislative proposals that would allow the commercial importation of prescription drugs for sale in the United States

AMCP supports a wide range of measures that strike a balance between market-oriented principles and prudent regulations. Pharmacy benefit managers (PBMs) help facilitate patient access to medication at an affordable price.

AMCP opposes attempts to erode the Employee Retirement Income Security Act (ERISA) and Medicare Part D preemption. AMCP believes that the certainty that comes with a single uniform federal standard ensures that plans subject to these laws are better able to provide access to needed medications regardless of where the patient lives or works.

The rebate system is an important lever for ensuring the affordability of prescription medications and health care premiums for Americans. AMCP supports the use of a rebate system as one of many levers to help to control drug costs.

AMCP encourages the use of generic drugs as safe, cost- effective alternatives to the equivalent brand-name products

Use of appropriate medication regimens, regardless of cost, may help to improve patients’ conditions, improve quality of life, and lower other health care costs.

AMCP urges policymakers and stakeholders to reject the criminalization of medication dispensing in favor of rigorous scientific standards used to determine the safest and most effective care for patients.

AMCP supports efforts to reduce fraud, waste, and abuse in prescription drug benefit plans

The Academy of Managed Care Pharmacy (AMCP) supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies.

The Academy of Managed Care Pharmacy (AMCP) supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies.

AMCP believes that a health care delivery system that is based upon a competitive marketplace will provide greater value to patients and payers than a system that is one‐size‐fits‐all that relies on centralized governmental controls and regulatory mandates.